This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
by Zacks Equity Research
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Here's Why Investors Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Here's Why You Should Retain AngioDynamics (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.
Stryker (SYK) to Boost Presence in China Via Digital Healthcare
by Zacks Equity Research
Stryker's (SYK) participation at the WIC in China marks a milestone for the company as it can bring more Advanced Digital Healthcare solutions to the China market.
Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Zacks.com featured highlights include Sanderson Farms, United Therapeutics, AMN Healthcare
by Zacks Equity Research
Sanderson Farms, United Therapeutics, AMN Healthcare are part of zacks Screen of the week article.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
McKesson's (MCK) Latest JV to Boost Cancer Treatment Options
by Zacks Equity Research
McKesson's (MCK) latest activities in the oncology care space is expected to serve a wider patient pool.
Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust performances across the U.S. pharmacy and retail business are likely to have contributed to Walgreens' (WBA) Q3 performance.
AMN Healthcare (AMN) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
AMN Healthcare (AMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
Buy These 3 Low-Beta Stocks to Sail Through a Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. United Therapeutics (UTHR), Sanderson (SAFM) and AMN Healthcare (AMN) are well poised to gain.
New Strong Buy Stocks for June 24th
by Zacks Equity Research
AMR, SBOW, AMN, BVH, and EGLE have been added to the Zacks Rank #1 (Strong Buy) List on June 24, 2022.
Where Do Pricy Tesla Shares Go from Here?
by John Blank
As important, does the S&P500 index follow along?
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.
UnitedHealth (UNH) Unit Unveils Solution to Provide Better Care
by Zacks Equity Research
UnitedHealth's (UNH) subsidiary Optum introduces a solution that can detect tests that are clinically backed, thereby minimizing unrequired tests and offering enhanced care to health plan members.
Tenet Healthcare (THC) Unit Ties Up to Boost Urology Services
by Zacks Equity Research
Tenet Healthcare's (THC) unit, USPI, signs a joint venture partnership with UUG to acquire ownership interests in the latter's 22 ambulatory surgery centers and concurrently assuring to develop these centers.
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.